MCC trials EU+US
BizInt Smart Charts Reference Rows 2.1.1
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:EUDRACT:2011-003226-27-GB
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003226-27/GB/
A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma
2011-003226-27
EudraCT 2011-003226-27
UKMCC-01, Version 1.0, 01-Jun-2012
RG_10-151
ISRCTN10125877
GlaxoSmithKline
Ongoing
Phase II
2019-07-30 (calculated)
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:EUDRACT:2014-004735-39-NL
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004735-39/NL/
Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
2014-004735-39
EudraCT 2014-004735-39
M14NEC
Novartis
Ongoing
Phase II
2017-10-19 (calculated)
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:EUDRACT:2016-000461-23-DE
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000461-23/DE/
An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
2016-000461-23
EudraCT 2016-000461-23
CheckMate 627
CA209-627
U1111-1179-0085
Bristol-Myers Squibb International Corporation
Ongoing
Phase II
2022-09-08 (calculated)
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT00655655
https://clinicaltrials.gov/show/NCT00655655
A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors
NCT00655655
MC0414
NCI-2009-01200
MC0414
P30CA015083
NCT00655655
National Cancer Institute (NCI)
Active, not recruiting
Phase 1
December 2017 (Anticipated)
2017-03-21
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT01013779
https://clinicaltrials.gov/show/NCT01013779
A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin
NCT01013779
TROG 09.03
ACTRN12610000480088
NCT01013779
Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting
Phase 2
December 2020 (Anticipated)
2017-07-10
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02584829
https://clinicaltrials.gov/show/NCT02584829
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab
NCT01440816
9245
NCI-2014-02462
FHCRC 9245
9245
P30CA015704
R01CA176841
NCT02584829
EMD Serono
Recruiting
Phase 1/Phase 2
2017-02-15
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02036476
https://clinicaltrials.gov/show/NCT02036476
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02036476
13-490
NCT02036476
Exelixis
Active, not recruiting
Phase 2
January 2019 (Anticipated)
2017-05-19
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02155647
https://clinicaltrials.gov/show/NCT02155647
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
NCT02155647
100070-003
2014-000445-79
NCT02155647
Merck KGaA
Recruiting
Phase 2
June 30, 2025 (Anticipated)
2017-07-13
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02196961
https://clinicaltrials.gov/show/NCT02196961
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With 3 mg/kg BW Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
NCT02196961
CA184-205
NCT02196961
Bristol-Myers Squibb
Recruiting
Phase 2
June 2018 (Anticipated)
2016-09-12
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02267603
https://clinicaltrials.gov/show/NCT02267603
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
NCT02267603
NCI-2014-00848
NCI-2014-00848
CITN-09
MK-3475
CITN-09
CITN-09
U01CA154967
NCT02267603
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
2017-06-30
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02351128
https://clinicaltrials.gov/show/NCT02351128
Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II.
NCT02351128
38RC14.040
2014-001273-13
NCT02351128
University Hospital, Grenoble
Recruiting
Phase 2
April 2019 (Anticipated)
2017-02-21
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02465957
https://clinicaltrials.gov/show/NCT02465957
Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)
NCT02465957
MCC-001
QUILT-3.009
NCT02465957
NantKwest, Inc.
Recruiting
Phase 2
December 2017 (Anticipated)
2017-06-09
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:EUDRACT:2015-000230-29-NL
https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000230-29/NL/
Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors
NCT02488759
EudraCT 2015-000230-29
CheckMate358
CA209-358
U1111-1166-0687
Bristol-Myers Squibb International Corporation
Ongoing
Phase I/Phase II
2018-05-17 (calculated)
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02514824
https://clinicaltrials.gov/show/NCT02514824
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02514824
15-223
NCT02514824
Millennium Pharmaceuticals, Inc.
Recruiting
Phase 1/Phase 2
July 2020 (Anticipated)
2017-05-19
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02643303
https://clinicaltrials.gov/show/NCT02643303
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
NCT02643303
LUD2014-011
NCT02643303
MedImmune LLC
Recruiting
Phase 1/Phase 2
August 2022 (Anticipated)
2017-07-11
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02819843
https://clinicaltrials.gov/show/NCT02819843
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
NCT02819843
16-224
NCT02819843
Amgen
Recruiting
Phase 2
June 2019 (Anticipated)
2017-02-22
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02831179
https://clinicaltrials.gov/show/NCT02831179
A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
NCT02831179
VICC GI 14134
NCI-2016-01044
NCT02831179
National Cancer Institute (NCI)
Not yet recruiting
Phase 1
February 2020 (Anticipated)
2017-07-14
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02890368
https://clinicaltrials.gov/show/NCT02890368
A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
NCT02890368
TTI-621-02
NCT02890368
Trillium Therapeutics Inc.
Recruiting
Phase 1
December 2019 (Anticipated)
2017-02-13
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02936323
https://clinicaltrials.gov/show/NCT02936323
A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung
NCT02936323
PEN-221-001
NCT02936323
Tarveda Therapeutics
Recruiting
Phase 1/Phase 2
December 2019 (Anticipated)
2017-06-28
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT02978625
https://clinicaltrials.gov/show/NCT02978625
A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
NCT02978625
NCI-2016-01804
NCI-2016-01804
10057
10057
P30CA072720
UM1CA186716
NCT02978625
National Cancer Institute (NCI)
Not yet recruiting
Phase 2
January 31, 2019 (Anticipated)
2017-06-30
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03000257
https://clinicaltrials.gov/show/NCT03000257
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
NCT03000257
M15-891
2016-002520-89
NCT03000257
AbbVie
Recruiting
Phase 1
September 18, 2019 (Anticipated)
2017-07-17
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03071406
https://clinicaltrials.gov/show/NCT03071406
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
NCT03071406
MCC-18786
CA209-737
NCT03071406
Bristol-Myers Squibb
Recruiting
Phase 2
July 2023 (Anticipated)
2017-03-30
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03071757
https://clinicaltrials.gov/show/NCT03071757
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757
M16-074
2016-004205-14
NCT03071757
AbbVie
Recruiting
Phase 1
October 27, 2019 (Anticipated)
2017-07-31
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03107663
https://clinicaltrials.gov/show/NCT03107663
A Phase I Study of Positron Emission Tomography With 89Zr-Df-IAB22M2C in Patients With Selected, Metastatic Solid Malignancies (Non Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma Head and Neck, Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma
NCT03107663
2015-22M2C-01
NCT03107663
ImaginAb, Inc.
Recruiting
Phase 1
May 2018 (Anticipated)
2017-08-02
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03126110
https://clinicaltrials.gov/show/NCT03126110
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NCT03126110
INCAGN 1876-201
NCT03126110
Incyte Biosciences International Sàrl
Recruiting
Phase 1/Phase 2
March 2020 (Anticipated)
2017-08-02
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03167164
https://clinicaltrials.gov/show/NCT03167164
NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy
NCT03167164
QUILT-3.045
NCT03167164
NantCell, Inc.
Not yet recruiting
Phase 1/Phase 2
March 2019 (Anticipated)
2017-06-27
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03212404
https://clinicaltrials.gov/show/NCT03212404
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
NCT03212404
CK-301-101
NCT03212404
Checkpoint Therapeutics, Inc.
Not yet recruiting
Phase 1
December 2020 (Anticipated)
2017-07-06
com.bizcharts:C#\bizint demo data\Merkel_Cell_Carcinoma_2017\VPSCE training files\MCC US+EU ongoing.chrr:NCT: NCT03241173
https://clinicaltrials.gov/show/NCT03241173
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NCT03241173
INCAGN 1949-201
NCT03241173
Incyte Corporation
Not yet recruiting
Phase 1/Phase 2
November 2021 (Anticipated)
2017-08-02